Related Experiment Video
Updated: Aug 13, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Abstract:
The first data from the phase II SERENA-2 trial look promising for the investigational oral selective estrogen receptor degrader camizestrant. Compared with standard fulvestrant, it significantly prolonged progression-free survival in postmenopausal women with advanced estrogen receptor-positive, HER2-negative breast cancer. Camizestrant also bested fulvestrant in subgroup analyses of patients who previously received a CDK4/6 inhibitor, had visceral metastases, or had ESR1 mutations.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
12:03Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma
Published on: July 25, 2011